

**SARS-CoV-2/Flu A/B/RSV Assay (Panther Fusion® System)**

For *in vitro* diagnostic use  
For U.S. Export only

**CONTENTS**

**General Information** ..... 2

- Intended Use ..... 2
- Summary and Explanation of the Test ..... 2
- Principles of the Procedure ..... 3
- Summary of Safety and Performance ..... 4
- Warnings and Precautions ..... 4
- Reagent Storage and Handling Requirements ..... 7
- Specimen Collection and Storage ..... 8
- Specimen Transport ..... 9

**Panther Fusion System** ..... 10

- Reagents and Materials Provided for Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay 10
- Materials Required and Available Separately ..... 11
- Panther Fusion System Test Procedure ..... 12
- Procedural Notes ..... 13

**Quality Control** ..... 14

**Interpretation of Results** ..... 14

**Limitations** ..... 16

**Analytical Performance** ..... 17

- Analytical Sensitivity ..... 17
- Reactivity-Wet Testing ..... 18
- Reactivity-In silico Analysis ..... 20
- Analytical Specificity and Microbial Interference ..... 21
- Competitive Interference ..... 23
- Interference ..... 24
- Assay Precision ..... 25
- Carryover Contamination ..... 26
- Collection Device Equivalency ..... 26

**Clinical Performance** ..... 27

- Clinical Study — NP Swab Specimens in VTM/UTM ..... 27
- Clinical Study — Nasal Swab Specimens ..... 30
- Reproducibility ..... 33

**Bibliography** ..... 36

**Contact Information** ..... 37

## General Information

### Intended Use

The Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay is a fully automated multiplexed real-time RT-PCR test intended for the qualitative detection and differentiation of RNA from SARS-CoV-2 virus, influenza A virus (Flu A), influenza B virus (Flu B) and respiratory syncytial virus (RSV) isolated and purified from nasopharyngeal (NP) swab specimens (collected by a healthcare professional) and nasal swab specimens (collected under observation of or by a healthcare professional) obtained from individuals exhibiting signs and symptoms of a respiratory tract infection. Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2, influenza and RSV can be similar. This assay is intended to aid in the differential diagnosis of SARS-CoV-2, influenza A virus, influenza B virus and RSV infections in humans and is not intended to detect influenza C virus infections. The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is intended for use by clinical laboratory personnel specifically instructed and trained in the operation of the Panther Fusion System and in vitro diagnostic procedures.

Negative results do not preclude SARS-CoV-2, influenza A virus, influenza B virus or RSV infections and should not be used as the sole basis for treatment or other management decisions. This assay is designed for use on the Panther Fusion system.

### Summary and Explanation of the Test

Respiratory viruses are responsible for a wide range of acute respiratory tract infections including the common cold, influenza (flu), RSV infection, COVID-19 and croup and represent the most common cause of acute illness in the United States. Some symptoms of COVID-19, flu and RSV are similar making diagnosis based on symptoms alone virtually impossible.<sup>1,2,3</sup>

Disease severity of flu and RSV can be especially high in the young, the immunocompromised, and elderly patients. Accurate and timely diagnosis of the cause of respiratory tract infections has many benefits. They include improved treatment of the patient by ensuring appropriate antiviral treatment (e.g. oseltamivir for influenza),<sup>4</sup> decreasing the overall cost of care, reducing the potential for further development of antimicrobial resistance due to excessive and inappropriate use of antibiotics,<sup>5</sup> assisting infection control personnel in providing appropriate measures to minimize nosocomial spread, and providing valued information to public health authorities regarding which viruses are circulating in the community.<sup>6</sup>

Influenza is an acute respiratory illness caused by infection with the influenza virus, primarily types A and B.<sup>7</sup> Influenza A viruses are further categorized into subtypes based on the two major surface protein antigens: hemagglutinin (H) and neuraminidase (N).<sup>8</sup> Influenza B viruses are not categorized into subtypes.<sup>8</sup> Influenza viruses continuously undergo genetic changes including drift (random mutation) and variation (genomic reassortment), generating new strains of virus each year, leaving the human population vulnerable to these seasonal changes. Epidemics occur yearly (typically in winter) and while both types A and B circulate in the population, type A is usually dominant. Transmission of influenza is primarily via airborne droplet (coughing or sneezing). Symptoms arise on average 1 to 2 days post-exposure and include fever, chills, headache, malaise, cough, and coryza.

Complications due to influenza include pneumonia causing increased morbidity and mortality in pediatric, elderly and immunocompromised populations. Influenza occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. Illnesses can result in

hospitalization and death mainly among high-risk groups (the very young, elderly or chronically ill). Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths.<sup>9</sup>

Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and children. There are 2 types of RSV (A and B) based on antigenic and surface protein variations. Most yearly epidemics (typically during winter) contain a mix of type A and B viruses, but one subgroup can dominate during a season. RSV infection can cause severe respiratory illness among all ages but is more prevalent in pediatric, elderly and immunocompromised populations. Annually in the United States, RSV infection has been associated with an estimated 58,000 to 80,000 hospitalizations and 2.1 million outpatient visits among children younger than 5 years, and 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths among adults older than 65 years.<sup>9</sup>

Coronaviruses are a large family of viruses which may cause illness in animals or humans. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus, SARS-CoV-2, causes the associated coronavirus disease COVID-19. This new virus and disease were unknown before outbreak in Wuhan, China, in December 2019.<sup>10</sup> People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with COVID-19 may exhibit fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and/or diarrhea.<sup>11</sup> On March 11, 2020, the COVID-19 outbreak was characterized as a pandemic by the World Health Organization (WHO).<sup>12</sup> Over 760 million cases and 6.9 million deaths have been recorded worldwide since December 2019, but the actual number is thought to be higher.<sup>13</sup>

## Principles of the Procedure

The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay involves the following steps: sample lysis, nucleic acid capture and elution transfer, and multiplex RT-PCR when analytes are simultaneously amplified, detected and differentiated. Nucleic acid capture and elution takes place in a single tube on the Panther Fusion system. The eluate is transferred to the Panther Fusion system reaction tube containing the assay reagents. Multiplex RT-PCR is then performed for the eluted nucleic acid on the Panther Fusion system.

**Nucleic acid capture and elution:** Prior to processing and testing on the Panther Fusion system, specimens collected in universal transport media (UTM) and viral transport medium (VTM) are transferred to a Specimen Lysis Tube containing specimen transport media (STM). Alternatively, samples can be collected with the RespDirect™ Collection Kit which contains enhanced specimen transport media (eSTM). STM and eSTM lyse the cells, releases target nucleic acid, and protects them from degradation during storage.

The Internal Control-S (IC-S) is added to each test specimen and controls via the working Panther Fusion Capture Reagent-S (wFCR-S). The IC-S in the reagent monitors specimen processing, amplification and detection.

Capture oligonucleotides hybridize to nucleic acid in the test specimen. Hybridized nucleic acid is then separated from the specimen in a magnetic field.

Wash steps remove extraneous components from the reaction tube. The elution step elutes purified nucleic acid. During the nucleic acid capture and elution step, total nucleic acid is isolated from specimens.

**Elution transfer and RT-PCR:** During the elution transfer step, eluted nucleic acid is transferred to a Panther Fusion reaction tube already containing oil and reconstituted mastermix.

Target amplification occurs via RT-PCR. A reverse transcriptase generates a DNA copy of the target sequence. Target specific forward and reverse primers and probes then amplify targets while simultaneously detecting and discriminating multiple target types via multiplex RT-PCR.

The Panther Fusion system compares the fluorescence signal to a predetermined cut-off to produce a qualitative result for the presence or absence of the analyte.

The analytes and the channel used for their detection on the Panther Fusion system is summarized in the table below.

Analyte	Gene Targeted	Instrument Channel
Influenza A Virus	Matrix	FAM
Respiratory Syncytial Virus A/B	Matrix	HEX
SARS-CoV-2	ORF1ab	ROX
Influenza B Virus	Matrix	RED647
Internal Control	Not applicable	RED677

## Warnings and Precautions



- A. For *in vitro* diagnostic use.
- B. Carefully read this entire package insert and the *Panther®/Panther Fusion System Operator's Manual*.
- C. For professional use.
- D. The Panther Fusion Enhancer Reagent-S (FER-S) is corrosive, harmful if swallowed and causes severe skin burns and eye damage.
- E. Only personnel adequately trained on the use of this assay and in handling potentially infectious materials should perform these procedures. If a spill occurs, immediately disinfect using appropriate site procedures.
- F. Specimens may be infectious. Use Universal Precautions when performing this assay. Proper handling and disposal methods should be established by the laboratory director. Only personnel adequately trained in handling infectious materials should be permitted to perform this diagnostic procedure.<sup>7</sup>

**Note:** *If SARS-CoV-2 or infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, collect specimens with appropriate infection control precautions for viruses and send to state or local health department for testing. Do not attempt viral culture in these cases unless a BSL 3+ facility is available to receive and culture specimens.*

- G. Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of being infected with SARS-CoV-2 as outlined in the CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019 Novel Coronavirus (SARS-CoV-2). Refer to Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019-nCoV. <https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html>.
- H. Use only supplied or specified disposable laboratory ware.
- I. Wear disposable, powderless gloves, protective eye wear, and laboratory coats when handling specimens and reagents. Wash hands thoroughly after handling specimens and reagents. Dispose of all material that has come into contact with specimens and reagents in accordance with applicable national, international, and regional regulations.
- J. Do not use the reagents and controls after the expiration date.
- K. Expiration dates listed on the RespDirect Collection Kit and the Panther Fusion Specimen Lysis Tubes pertain to the transfer of sample into the tube and not to testing of the sample. Specimens collected/transferred any time prior to these expiration dates are valid for testing provided they are transported and stored in accordance with the appropriate package insert, even if these expiration dates have passed.
- L. Maintain proper storage conditions during specimen shipping to ensure the integrity of the specimen. Specimen stability under shipping conditions other than those recommended has not been evaluated.
- M. Avoid cross-contamination during the specimen handling steps. Specimens can contain extremely high levels of virus or other organisms. Ensure that specimen containers do not come in contact with one another, and discard used materials without passing them over any open containers. Change gloves if they come in contact with specimens.
- N. Store assay components at the recommended storage condition. See *Reagent Storage and Handling Requirements* (page 7), and *Panther Fusion System Test Procedure* (page 12) for more information.
- O. Do not combine any assay reagents or fluids. Do not top off reagents or fluids; the Panther Fusion system verifies reagent levels.
- P. Avoid microbial and ribonuclease contamination of reagents.
- Q. Quality control requirements must be performed in conformance with local, state, and/or federal regulations or accreditation requirements and your laboratory's standard quality control procedures.
- R. Do not use the assay cartridge if the storage pouch has lost its seal or if the assay cartridge foil is not intact. Contact Hologic if either occurs.
- S. Do not use the fluid packs if the foil seal is leaking. Contact Hologic if this occurs.
- T. Handle the assay cartridges with care. Do not drop or invert assay cartridges. Avoid prolonged exposure to ambient light.

- U. Do not use material that may contain Guanidinium thiocyanate or any guanidine-containing materials on the instrument. Highly reactive and/or toxic compounds may form if combined with sodium hypochlorite.
- V. Some reagents in the kit are labeled with hazard information.

**Note:** Hazard communication reflects the EU Safety Data Sheet (SDS) classifications. For hazard communication information specific to your region, refer to the region specific SDS on the Safety Data Sheet Library at [www.hologicsds.com](http://www.hologicsds.com). For more information on the symbols, refer to the symbol legend on [www.hologic.com/package-inserts](http://www.hologic.com/package-inserts).

<b>EU Hazard Information</b>	
<p><b>Panther Fusion Capture Reagent-S (FCR-S)</b>  <i>Lauryl Sulfate Lithium Salt 0-10%</i>  <i>Succinic Acid 0-10%</i></p> <p>— —</p> <p>H402 - Harmful to aquatic life.            P273 - Avoid release to the environment.            P501 - Dispose of contents/ container to an approved waste disposal plant.</p>	
<p></p> <p><b>Panther Fusion Enhancer Reagent-S (FER-S)</b>  <i>Lithium Hydroxide, Monohydrate 5-10%</i></p> <p><b>DANGER</b></p> <p>H302 - Harmful if swallowed            H314 - Causes severe skin burns and eye damage</p> <p></p> <p>P264 - Wash face, hands and any exposed skin thoroughly after handling.            P270 - Do not eat, drink or smoke when using this product.            P330 - Rinse mouth.            P501 - Dispose of contents/ container to an approved waste disposal plant.            P260 - Do not breathe dust/fume/gas/mist/vapours/spray.            P280 - Wear protective gloves/protective clothing/eye protection/face protection.            P301 + P330 + P331 - IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.            P303 + P361 + P353 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water [or shower].            P304 + P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing.            P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.            P310 - Immediately call a POISON CENTER or doctor.            P321 - Specific treatment (see supplemental first aid instructions on the SDS).            P363 - Wash contaminated clothing before reuse.            P405 - Store locked up.</p>	

## Reagent Storage and Handling Requirements

A. The following table provides storage and handling requirements for this assay.

Reagent	Unopened Storage	On Board/ Open Stability <sup>1</sup>	Opened Storage
Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Cartridge	2°C to 8°C	60 days	2°C to 8°C <sup>2</sup>
Panther Fusion Capture Reagent-S (FCR-S)	15°C to 30°C	30 days	15°C to 30°C
Panther Fusion Enhancer Reagent-S (FER-S)	15°C to 30°C	30 days	15°C to 30°C
Panther Fusion Internal Control-S (IC-S)	2°C to 8°C	(In wFCR-S)	Not applicable
Panther Fusion Elution Buffer	15°C to 30°C	60 days	15°C to 30°C
Panther Fusion Oil	15°C to 30°C	60 days	15°C to 30°C
Panther Fusion Reconstitution Buffer I	15°C to 30°C	60 days	15°C to 30°C
Panther Fusion SARS-CoV-2/Flu A/B/RSV Positive Control	2°C to 8°C	Single use vial	Not applicable-single use
Panther Fusion Negative Control	2°C to 8°C	Single use vial	Not applicable-single use

When reagents are removed from the Panther Fusion system, return them immediately to their appropriate storage temperatures.

<sup>1</sup>On board stability starts at the time the reagent is placed on the Panther Fusion system for the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay cartridge, FCR-S, FER-S and IC-S. On board stability starts for the Panther Fusion Reconstitution Buffer I, Panther Fusion Elution Buffer, and Panther Fusion Oil when the reagent pack is first used.

<sup>2</sup>If removed from the Panther Fusion system, store the assay cartridge in an air-tight container with desiccant at the recommended storage temperature.

- B. Working Panther Fusion Capture Reagent-S and Panther Fusion Enhancer Reagent-S are stable for 60 days when capped and stored at 15°C to 30°C. Do not refrigerate.
- C. Discard any unused reagents that have surpassed their on board stability.
- D. Controls are stable until the date indicated on the vials.
- E. Avoid cross-contamination during reagent handling and storage.
- F. **Do not freeze reagents.**

## Specimen Collection and Storage

**Specimens** - Clinical material collected from patient placed in an appropriate transport system. For the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay, this includes NP and nasal swab specimens in viral transport medium (VTM), universal transport medium (UTM), or collected in eSTM with the RespDirect Collection Kit.

**Samples** - Represents a more generic term to describe any material for testing on the Panther Fusion system including specimens, specimens transferred into a Panther Fusion Specimen Lysis Tube and controls.

**Note:** *Handle all specimens as if they contain potentially infectious agents. Use Universal Precautions.*

**Note:** *Take care to avoid cross-contamination during specimen handling steps. For example, discard used material without passing over open tubes.*

## Specimen Collection

Collect NP or nasal swab specimens according to standard technique using a polyester-, rayon, or nylon-tipped swab. Immediately place the swab specimen into 3 mL of VTM or UTM. The Hologic RespDirect Collection Kit may be used for the collection of NP and nasal swab samples.

## Specimen Processing

### **Specimen Processing with the Panther Fusion Specimen Lysis Tube**

Prior to testing on the Panther Fusion system, transfer 500 µL of the specimen collected in UTM or VTM into a Panther Fusion Specimen Lysis Tube.

**Note:** *When testing frozen specimen, allow specimen to reach room temperature prior to processing.*

### **Specimen Processing with the Enhanced Direct Load Tube (RespDirect Collection Kit)**

After collecting the specimen into the Enhanced Direct Load Tube (RespDirect Collection Kit), the specimen may be loaded on the Panther Fusion system.

**Note:** *If clots are observed, samples may be vortexed for 5–10 minutes at 1,800 rpm on a multi-tube vortex (or setting 5 on Cat. No. 102160G).*

*Alternatively, individual tubes may be vortexed by hand for 15 seconds on max. speed on a standard bench top vortex.*

*If previously pierced, recap tubes with a new penetrable cap before vortexing.*

*If a CLT result is obtained upon retesting, collect a new sample.*

**Note:** *When testing frozen specimen, allow specimen to reach room temperature prior to loading on the Panther Fusion system.*

**Note:** *If the lab receives an Enhanced Direct Load Tube (RespDirect Collection Kit) with no swab or two swabs, the specimen must be rejected.*



## Specimen Storage

### *Storing Specimens with the Panther Fusion Specimen Lysis Tube*

1. After collection, specimens can be stored at 2°C to 8°C up to 96 hours before transferred to the Panther Fusion Specimen Lysis Tube. Remaining specimen volumes can be stored at ≤-70°C.
2. Samples (in the Panther Fusion Specimen Lysis Tube) can be stored under the following conditions:
  - 15°C to 30°C up to 6 days or
  - 2°C to 8°C, -20°C, and -70°C for up to 3 months
3. Previously tested samples should be covered with a new, clean plastic film or foil barrier.
4. If assayed samples need to be frozen or shipped, remove the penetrable cap and place a new non-penetrable cap on the specimen tubes. If samples need to be shipped for testing at another facility, recommended temperatures must be maintained. Prior to uncapping previously tested and recapped samples, specimen transport tubes must be centrifuged for 5 minutes at 420 Relative Centrifugal Force (RCF) to bring all of the liquid down to the bottom of the tube. Avoid splashing and cross-contamination.

### *Storing Specimens with the Enhanced Direct Load Tube (RespDirect Collection Kit)*

1. Samples can be stored under the following conditions:
  - 2°C to 30°C up to 6 days or
  - 2°C to 8°C, -20°C, and -70°C for up to 3 months.
2. Previously tested samples should be covered with a new, clean plastic film or foil barrier.
3. If assayed samples need to be frozen or shipped, remove the penetrable cap and place a new non-penetrable cap on the specimen tubes. If samples need to be shipped for testing at another facility, recommended temperatures must be maintained. Prior to uncapping previously tested and recapped samples, specimen tubes may be centrifuged for 5 minutes at 420 RCF to bring all of the liquid down to the bottom of the tube. Avoid splashing and cross-contamination.

## Specimen Transport

Maintain specimen storage conditions as described in the *Specimen Collection and Storage section on page 8*.

**Note:** *Specimens must be shipped in accordance with applicable national, international, and regional transportation regulations.*

## Panther Fusion System

The Panther Fusion System is an integrated nucleic acid testing system that fully automates all steps necessary to perform various Panther Fusion assays from sample processing through amplification, detection, and data reduction.

### Reagents and Materials Provided for Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

#### Assay Packaging

Components <sup>1</sup>	Part No.	Storage
<b>Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Cartridges 96 Tests</b> Panther Fusion SARS-CoV-2/Flu A/B/RSV assay cartridge, 12 tests, 8 per box	PRD-07400	2°C to 8°C
<b>Panther Fusion Internal Control-S 960 Tests</b> Panther Fusion Internal Control-S tube, 4 per box	PRD-04332	2°C to 8°C
<b>Panther Fusion SARS-CoV-2/Flu A/B/RSV Controls</b> Panther Fusion SARS-CoV-2/Flu A/B/RSV Positive Controls tube, 5 per box Panther Fusion Negative Control tube, 5 per box	PRD-07401	2°C to 8°C
<b>Panther Fusion Extraction Reagent-S 960 Tests</b> Panther Fusion Capture Reagent-S bottle, 240 tests, 4 per box Panther Fusion Enhancer Reagent-S bottle, 240 tests, 4 per box	PRD-04331	15°C to 30°C
<b>Panther Fusion Elution Buffer 2400 Tests</b> Panther Fusion Elution Buffer pack, 1200 tests, 2 per box	PRD-04334	15°C to 30°C
<b>Panther Fusion Reconstitution Buffer I 1920 Tests</b> Panther Fusion Reconstitution Buffer I pack, 960 tests, 2 per box	PRD-04333	15°C to 30°C
<b>Panther Fusion Oil 1920 Tests</b> Panther Fusion Oil pack, 960 tests, 2 per box	PRD-04335	15°C to 30°C

<sup>1</sup> Components can also be ordered in the following bundles:

Panther Fusion Universal Fluids Kit, PRD-04430, contains 1 each Panther Fusion Oil and Panther Fusion Elution buffer.

Panther Fusion Assay Fluids I-S, PRD-04431, contains 2 Panther Fusion Extraction Reagents-S, 2 Panther Fusion Internal Control-S, and 1 Panther Fusion Reconstitution Buffer I.

#### Individually Packaged Items

Items	Part No.
Panther Fusion Specimen Lysis Tubes, 100 per bag	PRD-04339
Hologic RespDirect Collection Kit, 50 per box	PRD-07403

## Materials Required and Available Separately

**Note:** Materials available from Hologic have catalog numbers listed, unless otherwise specified.

Material	Cat. No.
Panther® System	303095
Panther Fusion System	PRD-04172
Panther Fusion Module	PRD-04173
Panther System Continuous Fluid and Waste (Panther Plus)	PRD-06067
Aptima® Assay Fluids Kit (Aptima Wash Solution, Aptima Buffer for Deactivation Fluid, and Aptima Oil Reagent)	303014 (1000 tests)
Multi-tube units (MTUs)	104772-02
Panther Waste Bag Kit	902731
Panther Waste Bin Cover	504405
Or Panther System Run Kit for Real Time Assays contains MTUs, waste bags, waste bin covers, and assay fluids	PRD-03455 (5000 tests)
Or Panther System Run Kit (when running TMA assays in parallel with real time-TMA assays) contains MTUs, waste bags, waste bin covers, auto detect*, and assay fluids	303096 (5000 tests)
Panther Fusion Tube Trays, 1008 tests, 18 trays per box	PRD-04000
Tips, 1000 µL, filtered, liquid-sensing, conductive, and disposable.	901121 (10612513 Tecan) 903031 (10612513 Tecan)
<i>Not all products are available in all regions. Contact your representative for region-specific information.</i>	MME-04134 (30180117 Tecan) MME-04128
Aptima penetrable caps (optional)	105668
Replacement non-penetrable caps (optional)	103036A
Replacement extraction reagent bottle caps	CL0040
P1000 pipettor and tips with hydrophobic plugs	-
Bleach, 5% to 8.25% (0.7 M to 1.16 M) sodium hypochlorite solution <b>Note:</b> Refer to the <i>Panther/Panther Fusion System Operator's Manual</i> for instructions on preparing diluted sodium hypochlorite solution.	-
Disposable powderless gloves	-

\*Needed only for Panther Aptima TMA assays.

## Optional Materials

Material	Cat. No.
Multitube Vortex	102160G
Benchtop Vortex	-

## Panther Fusion System Test Procedure

**Note:** Refer to the Panther/Panther Fusion System Operator's Manual for additional procedural information.

### A. Work Area Preparation

1. Wipe down work surfaces with 2.5% to 3.5% (0.35 M to 0.5 M) sodium hypochlorite solution. Allow the sodium hypochlorite solution to contact surfaces for at least 1 minute and follow with a deionized (DI) water rinse. Do not allow the sodium hypochlorite solution to dry. Cover the bench surface with clean, plastic-backed absorbent laboratory bench covers.
2. Clean a separate work surface where samples will be prepared using the procedure described in step A.1.

### B. Reagent Preparation

1. Remove the bottles of IC-S, FCR-S and FER-S from storage.
2. Open the bottles of IC-S, FCR-S and FER-S, and discard the caps. Open the TCR door on the upper bay of the Panther Fusion system.
3. Place the IC-S, FCR-S and FER-S bottles in the appropriate positions on the TCR carousel.
4. Close the TCR door.

**Note:** The Panther Fusion system adds the IC-S to the FCR-S. After the IC-S is added to the FCR-S, it is referred to as wFCR-S (working FCR-S). If the FCR-S and FER-S are removed from the system, use new caps and immediately store according to the proper storage conditions.

### C. Specimen Handling

**Note:** Prepare specimens per the Specimen Processing instructions in the Specimen Collection and Storage section before loading specimens onto the Panther Fusion system.

Inspect sample tubes before loading into the rack. If a sample tube contains bubbles or has a lower volume than is typically observed, gently tap the bottom of the tube to bring contents to the bottom.

**Note:** To avoid a processing error, ensure adequate specimen volume is added to the Panther Fusion Specimen Lysis Tube. When 500  $\mu$ L of NP or nasal swab specimen is added to the Panther Fusion Specimen Lysis Tube, there is sufficient volume to perform 3 nucleic acid extractions.

**Note:** For the Enhanced Direct Load Tube (RespDirect Collection Kit), there is sufficient volume to perform 4 nucleic acid extractions.

### D. System Preparation

For instructions on setting up the Panther Fusion system including loading samples, reagents, assay cartridges and universal fluids, refer to the Panther/Panther Fusion System Operator's Manual.

## Procedural Notes

### A. Controls

1. The Panther Fusion SARS-CoV-2/Flu A/B/RSV Positive Control and Panther Fusion Negative Control can be loaded in any rack position, in any Sample Bay lane on the Panther Fusion system.
2. Once the control tubes are pipetted and are processed for the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay, they are active for up to 30 days (control frequency configured by an administrator) unless control results are invalid or a new assay cartridge lot is loaded.
3. Each control tube can be tested once.
4. Patient specimen pipetting begins when one of the following two conditions is met:
  - a. Valid results for the controls are registered on the system.
  - b. A pair of controls is currently in process on the system.

## Quality Control

A run or specimen result may be invalidated by the Panther Fusion system if problems occur while performing the assay. Specimens with invalid results must be retested.

### Negative and Positive Controls

To generate valid results, a set of assay controls must be tested. One replicate of the negative assay control and positive assay control must be tested each time a new lot of assay cartridges is loaded on the Panther Fusion system or when the current set of valid controls for an active cartridge lot have expired.

The Panther Fusion system is configured to require assay controls run at an administrator-specified interval of up to 30 days. Software on the Panther Fusion system alerts the operator when assay controls are required and does not start new tests until the assay controls are loaded and have started processing.

During processing, criteria for acceptance of the assay controls are automatically verified by the Panther Fusion system. To generate valid results, the assay controls must pass a series of validity checks performed by the Panther Fusion system.

If the assay controls pass all validity checks, they are considered valid for the administrator-specified time interval. When the time interval has passed, the assay controls are expired by the Panther Fusion system and requires a new set of assay controls be tested prior to starting any new samples.

If any one of the assay controls fails the validity checks, the Panther Fusion system automatically invalidates the affected samples and requires a new set of assay controls be tested prior to starting any new samples.

### Internal Control

An internal control is added to each sample during the extraction process. During processing, the internal control acceptance criteria is automatically verified by the Panther Fusion system software. Detection of the internal control is not required for samples that are positive for SARS-CoV-2, Flu A, Flu B and/or RSV. The internal control must be detected in all samples that are negative for SARS-CoV-2, Flu A, Flu B, and RSV; samples that fail to meet that criteria will be reported as Invalid. Each sample with an Invalid result must be retested.

The Panther Fusion system is designed to accurately verify processes when procedures are performed following the instructions provided in this package insert and the *Panther/Panther Fusion System Operator's Manual*.

## Interpretation of Results

The Panther Fusion system automatically determines the test results for samples and controls. Results for SARS-CoV-2, Flu A, Flu B, and RSV detection are reported separately. A test result may be negative, positive, or invalid.

Table 1 shows the possible results reported in a valid run with result interpretations.

Table 1: Result Interpretation

SARS-CoV-2 Result	Flu A Result	Flu B Result	RSV Result	IC Result	Interpretation
Neg	Neg	Neg	Neg	Valid	SARS-CoV-2, Flu A, Flu B, and RSV not detected.
Neg	POS	Neg	Neg	Valid	Flu A detected. SARS-CoV-2, Flu B, and RSV not detected.
Neg	Neg	POS	Neg	Valid	Flu B detected. SARS-CoV-2, Flu A, and RSV not detected.
Neg	Neg	Neg	POS	Valid	RSV detected. SARS-CoV-2, Flu A, and Flu B not detected.
POS	Neg	Neg	Neg	Valid	SARS-CoV-2 detected. Flu A, Flu B, and RSV not detected.
Neg	POS	POS	Neg	Valid	Flu A and Flu B detected. SARS-CoV-2 and RSV not detected.
Neg	Neg	POS	POS	Valid	Flu B and RSV detected. SARS-CoV-2 and Flu A not detected.
Neg	POS	Neg	POS	Valid	Flu A and RSV detected. SARS-CoV-2 and Flu B not detected.
POS	POS	Neg	Neg	Valid	SARS-CoV-2 and Flu A detected. Flu B and RSV not detected.
POS	Neg	POS	Neg	Valid	SARS-CoV-2 and Flu B detected. Flu A and RSV not detected.
POS	Neg	Neg	POS	Valid	SARS-CoV-2 and RSV detected. Flu A and Flu B not detected.
Neg	POS	POS	POS	Valid	Flu A, Flu B, and RSV detected. SARS-CoV-2 not detected. Triple infections are rare. Retest to confirm result.
POS	Neg	POS	POS	Valid	SARS-CoV-2, Flu B, and RSV detected. Flu A not detected. Triple infections are rare. Retest to confirm result.
POS	POS	Neg	POS	Valid	SARS-CoV-2, Flu A, and RSV detected. Flu B not detected. Triple infections are rare. Retest to confirm result.
POS	POS	POS	Neg	Valid	SARS-CoV-2, Flu A, and Flu B detected. RSV not detected. Triple infections are rare. Retest to confirm result.
POS	POS	POS	POS	Valid	SARS-CoV-2, Flu A, Flu B, and RSV detected. Quadruple infections are rare. Retest to confirm result.
Invalid	Invalid	Invalid	Invalid	Invalid	Invalid. There was an error in the generation of the result; retest sample.

Note: POS result will be accompanied by cycle threshold (Ct) values.

Note: Detection of internal control is not required for samples that are positive for SARS-CoV-2, Flu A, Flu B, and/or RSV.

## Limitations

- A. This product can be used only with the Panther Fusion System.
- B. Use of this assay is limited to personnel who are trained in the procedure. Failure to follow these instructions may result in erroneous results.
- C. Reliable results are dependent on adequate specimen collection, transport, storage, and processing.
- D. Avoid contamination by adhering to good laboratory practices and to the procedures specified in this package insert.
- E. Negative results do not preclude SARS-CoV-2, influenza A virus, influenza B virus, or RSV infections and should not be used as the sole basis for treatment or other management decisions.
- F. This test does not differentiate influenza A subtypes (i.e. H1N1, H3N2) or RSV subgroups (i.e., A or B); additional testing is required to differentiate any specific influenza A subtypes or strains or specific RSV subgroups, in consultation with local public health departments.
- G. A positive result indicates the detection of nucleic acid from the relevant virus. Nucleic acid may persist even after the virus is no longer viable.
- H. The performance of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay has not been specifically evaluated for NP swab specimens in a population known to be vaccinated against illnesses caused by any of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay analytes (e.g. SARS-CoV-2 (COVID-19) or, influenza, etc.).
- I. The performance of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay has not been established for monitoring treatment of infection with any of the panel organisms.
- J. The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay may not be able to distinguish between existing viral strains and new variants as they emerge.



## Analytical Performance

### Analytical Sensitivity

The analytical sensitivity (limit of detection or LoD) of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was determined by testing dilutions of processed negative clinical nasopharyngeal (NP) swab VTM/UTM matrix spiked with the WHO International Standard for SARS-CoV-2, NIBSC (20/146) or viral cultures of SARS-CoV-2 (1 strain), Influenza A (2 strains), Influenza B (2 strains), RSV A and RSV B (1 strain each). A minimum of 24 replicates were tested with each of three reagent lots. The LoD for each target was determined by Probit analysis for each reagent lot and was confirmed with an additional 24 replicates using a single reagent lot. Analytical sensitivity is defined as the lowest concentration at which  $\geq 95\%$  of all replicates tested positive, as summarized in Table 2.

LoD testing was also performed with the RespDirect Collection Kit. Negative clinical eSTM matrix was spiked with the WHO International Standard for SARS-CoV-2 and 1 strain each for Flu A, Flu B, RSV A, and RSV B. Thirty replicates were tested with a single reagent lot. The lowest concentration that observed  $\geq 95\%$  detection was 98.6 IU/mL for the WHO International Standard for SARS-CoV-2, 0.11 TCID<sub>50</sub>/mL for Influenza A/Kansas/14/17 (H3N2), 0.03 TCID<sub>50</sub>/mL for Influenza B/Washington/02/19 (Victoria lineage), 0.03 TCID<sub>50</sub>/mL for RSV A and 0.05 TCID<sub>50</sub>/mL for RSV B.

**Note:** The stated LoDs pertain to the concentrations in the tubes loaded onto the instrument. For samples collected in VTM/UTM, this is the concentration in the processed sample in an SLT. For samples collected using the RespDirect Collection Kit, this is the concentration in the Enhanced Direct Load tube (RespDirect Collection Kit).

Table 2: Analytical Sensitivity

Viral Strain/Standard	LoD concentration in the processed sample*	Units
WHO International Standard SARS-CoV-2, NIBSC (20/146)	47.20	IU/mL
SARS-CoV-2 USA-WA1/2020	0.03	TCID <sub>50</sub> /mL
Influenza A/Brisbane/02/18 (H1N1)	0.06	TCID <sub>50</sub> /mL
Influenza A/Kansas/14/17 (H3N2)	0.10	TCID <sub>50</sub> /mL
Influenza B/Washington/02/19 (Victoria lineage)	0.03	TCID <sub>50</sub> /mL
Influenza B/Phuket/3073/13 (Yamagata lineage)	0.003	TCID <sub>50</sub> /mL
RSV A	0.03	TCID <sub>50</sub> /mL
RSV B	0.03	TCID <sub>50</sub> /mL

\*Processed sample: 0.50 mL VTM/UTM primary clinical sample + 0.71 mL STM in an SLT

## Reactivity-Wet Testing

The reactivity of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was determined by testing virus strains in the processed negative clinical NP swab VTM/UTM matrix. Each strain was tested in triplicate at ~3X LoD with one reagent lot. For strains not detected at 3X LoD, additional testing at higher concentrations was performed until 100% positivity was observed. Table 3 shows the lowest concentration of each strain in which 100% positivity was observed.

Table 3: Analytical Reactivity Summary for SARS-CoV-2, Flu A and Flu B and RSV Strains

Description	Subtype	Concentration	SARS-CoV-2	Flu A	Flu B	RSV
USA-WA1/2020*	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA-CA1/2020	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA-AZ1/2020	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA-WI1/2020	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/OR-OHSU-PHL00037/ 2021 B.1.1.7	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
Uganda/MUWRP-20200195568/ 2020 A.23.1	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/PHC658/2021 B.1.617.2	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/MD-HP05285/2021 B.1.617.2	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/CA/VRLC009/2021 B.1.427	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/CA/VRLC012/2021 P.2	SARS-CoV-2	0.30 TCID <sub>50</sub> /mL	+	-	-	-
USA/MD-HP03056/2021 B.1.525	SARS-CoV-2	0.30 TCID <sub>50</sub> /mL	+	-	-	-
USA/CA-Stanford-16_S02/ 2021 B.1.617.1	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
Peru/un-CDC-2-4069945/ 2021 C.37	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/MD-HP20874/2021 B.1.1.529	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
USA/GA-EHC-2811C/ 2021 B.1.1.529	SARS-CoV-2	0.09 TCID <sub>50</sub> /mL	+	-	-	-
A/Brisbane/02/18*	Flu A (H1N1)	0.18 TCID <sub>50</sub> /mL	-	+	-	-
A/Michigan/45/2015	Flu A (H1N1)	0.18 TCID <sub>50</sub> /mL	-	+	-	-
A/Christ Church/16/2010	Flu A (H1N1)	180 <sup>1</sup> TCID <sub>50</sub> /mL	-	+	-	-
A/Kentucky/2/06	Flu A (H1N1)	0.60 TCID <sub>50</sub> /mL	-	+	-	-
A/Solomon Islands/03/06	Flu A (H1N1)	0.60 TCID <sub>50</sub> /mL	-	+	-	-
A/Guangdong-maonan/1536/2019	Flu A (H1N1)	180 <sup>1</sup> TCID <sub>50</sub> /mL	-	+	-	-
A/Taiwan/42/2006	Flu A (H1N1)	0.60 TCID <sub>50</sub> /mL	-	+	-	-
A/Henan/8/05	Flu A (H1N1)	0.60 TCID <sub>50</sub> /mL	-	+	-	-
A/Hawaii/15/01	Flu A (H1N1)	18 <sup>3</sup> TCID <sub>50</sub> /mL	-	+	-	-

Table 3: Analytical Reactivity Summary for SARS-CoV-2, Flu A and Flu B and RSV Strains (Continued)

Description	Subtype	Concentration	SARS-CoV-2	Flu A	Flu B	RSV
A/California/07/2009	Flu A (H1N1)	0.18 TCID <sub>50</sub> /mL	-	+	-	-
A/Hawaii/66/2019	Flu A (H1N1)	180 CEID <sub>50</sub> /mL	-	+	-	-
A/Indiana/02/2020	Flu A (H1N1)	60 CEID <sub>50</sub> /mL	-	+	-	-
A/Michigan/45/2015 pdm09-like virus	Flu A (H1N1)	0.60 TCID <sub>50</sub> /mL	-	+	-	-
A/Kansas/14/17*	Flu A (H3N2)	0.33 TCID <sub>50</sub> /mL	-	+	-	-
A/Arizona/45/2018	Flu A (H3N2)	3.3 FFU/mL	-	+	-	-
A/New York/21/2020	Flu A (H3N2)	3.3 FFU/mL	-	+	-	-
A/Hong Kong/45/2019	Flu A (H3N2)	3.3 FFU/mL	-	+	-	-
A/Singapore/INFIMH-16-0019/2016	Flu A (H3N2)	110 CEID <sub>50</sub> /mL	-	+	-	-
A/Hong Kong/2671/2019	Flu A (H3N2)	11 <sup>2</sup> TCID <sub>50</sub> /mL	-	+	-	-
A/Hiroshima/52/05	Flu A (H3N2)	1.1 TCID <sub>50</sub> /mL	-	+	-	-
A/Costa Rica/07/99	Flu A (H3N2)	11 <sup>3</sup> TCID <sub>50</sub> /mL	-	+	-	-
A/Port Chalmers/1/73	Flu A (H3N2)	1.1 TCID <sub>50</sub> /mL	-	+	-	-
A/Brazil/113/99	Flu A (H3N2)	1.1 TCID <sub>50</sub> /mL	-	+	-	-
A/Perth/16/2009	Flu A (H3N2)	0.33 TCID <sub>50</sub> /mL	-	+	-	-
A/Texas/50/2012	Flu A (H3N2)	0.33 TCID <sub>50</sub> /mL	-	+	-	-
A/Hong Kong/4801/2014	Flu A (H3N2)	1.1 TCID <sub>50</sub> /mL	-	+	-	-
A/Indiana/08/2011	Flu A (H3N2)	1.1 TCID <sub>50</sub> /mL	-	+	-	-
A/Hong Kong/486/97	Flu A (H5N1)	0.01 ng/mL	-	+	-	-
B/Washington/02/2019*	Flu B (Victoria)	0.09 TCID <sub>50</sub> /mL	-	-	+	-
B/Colorado/06/2017	Flu B (Victoria)	0.09 TCID <sub>50</sub> /mL	-	-	+	-
B/Florida/78/2015	Flu B (Victoria)	0.30 TCID <sub>50</sub> /mL	-	-	+	-
B/Alabama/2/17	Flu B (Victoria)	0.09 TCID <sub>50</sub> /mL	-	-	+	-
B/Ohio/1/2005	Flu B (Victoria)	0.30 TCID <sub>50</sub> /mL	-	-	+	-
B/Michigan/09/2011	Flu B (Victoria)	3 <sup>3</sup> TCID <sub>50</sub> /mL	-	-	+	-
B/Hawaii/01/2018 (NA D197N)	Flu B (Victoria)	0.90 <sup>1</sup> TCID <sub>50</sub> /mL	-	-	+	-
B/Brisbane/33/08	Flu B (Victoria)	0.09 TCID <sub>50</sub> /mL	-	-	+	-
B/Phuket/3073/2013*	Flu B (Yamagata)	0.006 TCID <sub>50</sub> /mL	-	-	+	-
B/Wisconsin/1/2010	Flu B (Yamagata)	2 <sup>1</sup> TCID <sub>50</sub> /mL	-	-	+	-
B/Utah/9/14	Flu B (Yamagata)	0.006 TCID <sub>50</sub> /mL	-	-	+	-
B/St. Petersburg/04/06	Flu B (Yamagata)	0.06 TCID <sub>50</sub> /mL	-	-	+	-

Table 3: Analytical Reactivity Summary for SARS-CoV-2, Flu A and Flu B and RSV Strains (Continued)

Description	Subtype	Concentration	SARS-CoV-2	Flu A	Flu B	RSV
B/Texas/81/2016	Flu B (Yamagata)	2 TCID <sub>50</sub> /mL	-	-	+	-
B/Indiana/17/2017	Flu B (Yamagata)	0.60 <sup>1</sup> TCID <sub>50</sub> /mL	-	-	+	-
B/Oklahoma/10/2018	Flu B (Yamagata)	2 <sup>1</sup> TCID <sub>50</sub> /mL	-	-	+	-
B/Massachusetts/02/2012	Flu B (Yamagata)	0.2 <sup>2</sup> TCID <sub>50</sub> /mL	-	-	+	-
B/Lee/40	Flu B	0.09 TCID <sub>50</sub> /mL	-	-	+	-
RSV-A/2006 Isolate*	RSVA	0.06 TCID <sub>50</sub> /mL	-	-	-	+
RSV A/4/2015 isolate #1	RSVA	0.06 TCID <sub>50</sub> /mL	-	-	-	+
RSV A/A2	RSVA	0.06 TCID <sub>50</sub> /mL	-	-	-	+
RSV A/12/2014 isolate #2	RSVA	0.06 TCID <sub>50</sub> /mL	-	-	-	+
RSV-B/CH93(18)-18*	RSVB	0.30 TCID <sub>50</sub> /mL	-	-	-	+
RSV B/3/2015 isolate #1	RSVB	0.09 TCID <sub>50</sub> /mL	-	-	-	+
RSV B/9320	RSVB	0.09 TCID <sub>50</sub> /mL	-	-	-	+

\*Strain used to establish LoD.

<sup>1</sup>In silico analysis showed 100% homology to amplification region. Virus stock degradation or error in TCID<sub>50</sub>/mL quantification may have impacted the concentration at 100% detection.

<sup>2</sup> In silico analysis identified a single mismatch in the forward and reverse primers for A/Hong Kong/2671/2019 and a single mismatch in the reverse primer of B/Massachusetts/02/2012. Due to the location of the mismatches, amplification and detection are not expected to be impacted. Virus stock degradation or error in TCID<sub>50</sub>/mL quantification may have impacted the concentration at 100% detection.

<sup>3</sup>Sequence of strain in targeted amplification regions are not available in NCBI or GISAID to further evaluate sensitivity.

## Reactivity-In silico Analysis

The inclusivity of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was evaluated using in silico analysis of the forward primers, reverse primers, and probes for the SARS-CoV-2, Flu A, Flu B and RSV target systems in relation to sequences available in the NCBI and GISAID gene databases. Any sequence with missing or ambiguous sequence information was removed from the analysis for that target region.

Based on the in silico analysis of GISAID and NCBI sequences available up to June 25, 2023 for SARS-CoV-2 (10% random sampling of >10 million sequences), the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is predicted to detect all 1,075,864 SARS-CoV-2 sequences evaluated.

The sequences evaluated included lineages and variants of concern (VOC) or variants under investigation (VUI) that may have important epidemiological, immunological, or pathogenic properties from a public health perspective, such as Delta and Omicron variants. All lineages and variants of public health interest identified as of June 25, 2023 are predicted to be detected; new sequences and variants will continue to be monitored for impacts on detection by the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay.

Based on in silico analysis of all sequences available from January 01, 2015 to July 12, 2023 in GISAID and NCBI databases, the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is predicted

to detect ≥99.99% of 135,897 Flu A, ≥99.90% of 37,582 Flu B, ≥97.65% of 2,425 RSV A, and ≥98.90% of 2,094 RSV B sequences evaluated.

### Analytical Specificity and Microbial Interference

Analytical specificity (cross-reactivity) and microbial interference with the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay were evaluated in the presence of closely related and non-targeted organisms. Panels consisting of 41 organisms (Table 4) were tested in processed negative clinical NP swab VTM/UTM matrix in the absence or presence of 3X LoD SARS-CoV-2, Flu A, Flu B and RSV. Bacteria were tested at  $10^6$  CFU/mL and viruses were tested at  $10^5$  TCID<sub>50</sub>/mL, except where noted. No cross-reactivity or microbial interference was observed for any of the 41 organisms tested with the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay at the following concentrations.

In silico cross-reactivity analysis of 143 respiratory organisms (545 GenBank accession numbers) predicted no cross reactivity or microbial interference with the exception of *S. marcescens* which had a possibility of low amplification without detection. Wet-testing in processed negative clinical NP swab VTM/UTM matrix of each target at 3X LoD in the presence of this organism at  $10^6$  CFU/mL demonstrated that no interference was observed.

Table 4: Cross Reactivity and Microbial Interference Microorganisms

Microorganism	Concentration <sup>1</sup>	Microorganism	Concentration <sup>1</sup>
Adenovirus 1	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Bordetella pertussis</i>	1x10 <sup>6</sup> CFU/mL
Adenovirus 7a	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Candida albicans</i>	1x10 <sup>6</sup> CFU/mL
CMV Strain AD 169	1x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Chlamydomphila pneumoniae</i>	1x10 <sup>6</sup> IFU/mL
Human coronavirus 229E	1x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Corynebacterium diphtheriae</i>	1x10 <sup>6</sup> CFU/mL
Human coronavirus NL63	1x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Escherichia coli</i>	1x10 <sup>6</sup> CFU/mL
Human coronavirus OC43	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Haemophilus influenzae</i>	1x10 <sup>6</sup> CFU/mL
Epstein-Barr virus (EBV)	1x10 <sup>6</sup> copies/mL	<i>Lactobacillus plantarum</i>	1x10 <sup>6</sup> CFU/mL
Enterovirus (e.g. EV68)	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Legionella pneumophila</i>	1x10 <sup>6</sup> CFU/mL
Human coronavirus HKU1 <sup>2</sup>	1x10 <sup>6</sup> copies/mL	<i>Moraxella catarrhalis</i>	1x10 <sup>5</sup> CFU/mL
Human Metapneumovirus (hMPV)	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Mycobacterium tuberculosis</i>	1x10 <sup>9</sup> rRNA copies/mL
HPIV-1	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Mycoplasma pneumoniae</i>	1x10 <sup>9</sup> rRNA copies/mL
HPIV-2	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Neisseria spp</i>	1x10 <sup>6</sup> CFU/mL
HPIV-3	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Neisseria meningitides</i>	1x10 <sup>6</sup> CFU/mL
HPIV-4	1x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Neisseria mucosa</i>	1x10 <sup>6</sup> CFU/mL
Measles	1x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Pneumocystis jirovecii</i>	1x10 <sup>6</sup> CFU/mL
MERS-Coronavirus	5x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Pseudomonas aeruginosa</i>	1x10 <sup>6</sup> CFU/mL
Mumps virus	1x10 <sup>5</sup> TCID <sub>50</sub> /mL	<i>Staphylococcus aureus</i>	1x10 <sup>6</sup> CFU/mL
Rhinovirus 1A	1x10 <sup>4</sup> TCID <sub>50</sub> /mL	<i>Staphylococcus epidermidis</i>	1x10 <sup>6</sup> CFU/mL
SARS coronavirus 1 <sup>2</sup>	1x10 <sup>6</sup> copies/mL	<i>Streptococcus pneumoniae</i>	1x10 <sup>6</sup> CFU/mL
Varicella Zoster Virus	1x10 <sup>3</sup> TCID <sub>50</sub> /mL	<i>Streptococcus pyogenes</i>	1x10 <sup>6</sup> CFU/mL
		<i>Streptococcus salivarius</i>	1x10 <sup>6</sup> CFU/mL

<sup>1</sup>CFU = Colony Forming Units; IFU = Inclusion Forming Units; TCID<sub>50</sub> = Median Tissue Culture Infectious Dose

<sup>2</sup>Cultured virus and whole genome purified nucleic acid for Human HKU1 and SARS-coronavirus are not readily available. HKU1 and SARS-coronavirus *in vitro* transcript (IVT) corresponding to the ORF1a gene regions targeted by the assay were used to evaluate cross-reactivity and microbial interference.

## Competitive Interference

Competitive interference in the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was evaluated in triplicate using pairs of targeted viruses at low/high concentrations in processed negative clinical NP swab VTM/UTM matrix. The low concentration was tested at 3X LoD, against a higher concentration of competing virus (up to 1.0E+4 TCID<sub>50</sub>/mL). If less than 100% positivity was observed for the low concentration virus (Target 1), the high concentration virus (Target 2) was diluted until a concentration was reached where 100% positivity of Target 1 was achieved. The highest concentration of competing virus (Target 2) that maintained 100% positivity for the low concentration virus (Target 1) is shown in Table 5.

Table 5: *Competitive Interference*

Target 1		Target 2		SARS-CoV-2 % detected	Flu A % detected	Flu B % detected	RSV % detected
Virus	3X LoD (TCID <sub>50</sub> /mL)	Virus	High Concentration (TCID <sub>50</sub> /mL)				
SARS-CoV-2	9.0E-2	Flu A	1.0E+4	<b>100%</b>	<b>100%</b>	0%	0%
		Flu B	1.0E+4	<b>100%</b>	0%	<b>100%</b>	0%
		RSV A	1.0E+4	<b>100%</b>	0%	0%	<b>100%</b>
		RSV B	3.0E+1	<b>100%</b>	0%	0%	<b>100%</b>
Flu A	3.3E-1	SARS-CoV-2	1.0E+2	<b>100%</b>	<b>100%</b>	0%	0%
		Flu B	1.0E+4	0%	<b>100%</b>	<b>100%</b>	0%
		RSV A	1.0E+4	0%	<b>100%</b>	0%	<b>100%</b>
		RSV B	3.0E+1	0%	<b>100%</b>	0%	<b>100%</b>
Flu B	9.0E-2	SARS-CoV-2	1.0E+4	<b>100%</b>	0%	<b>100%</b>	0%
		Flu A	1.0E+4	0%	<b>100%</b>	<b>100%</b>	0%
		RSV A	1.0E+4	0%	0%	<b>100%</b>	<b>100%</b>
		RSV B	1.0E+3	0%	0%	<b>100%</b>	<b>100%</b>
RSV A	6.0E-2	SARS-CoV-2	1.0E+4	<b>100%</b>	0%	0%	<b>100%</b>
		Flu A	1.0E+4	0%	<b>100%</b>	0%	<b>100%</b>
		Flu B	1.0E+4	0%	0%	<b>100%</b>	<b>100%</b>
RSV B	9.0E-2	SARS-CoV-2	1.0E+4	<b>100%</b>	0%	0%	<b>100%</b>
		Flu A	1.0E+4	0%	<b>100%</b>	0%	<b>100%</b>
		Flu B	1.0E+4	0%	0%	<b>100%</b>	<b>100%</b>

## Interference

Interfering endogenous and exogenous substances (mucin, whole blood, other potential medications and over-the-counter products) that may be present in a specimen were evaluated in the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. Clinically relevant concentrations of potentially interfering substances were added to processed clinical negative NP swab VTM/UTM matrix and tested in the absence and presence of SARS-CoV-2, Flu A, Flu B and RSV cultured virus at their respective 3X LoD concentrations. Tests were performed in triplicate. The substances and concentrations are shown in Table 6.

No impact on the performance of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was seen for any of the substances at the concentrations tested.

Table 6: Potentially Interfering Substances

Substance Type	Substance Name	Active Ingredient(s)	Concentration <sup>1</sup>
Endogenous	Mucin	Purified mucin protein	60 µg/mL
	Blood (human)	N/A	2% v/v
Nasal sprays or drops	Neo-Syneprine®	Phenylephrine	15% v/v
	Anefrin	Oxymetazoline	15% v/v
	Saline	Sodium chloride	15% v/v
	Ventolin HFA <sup>2</sup>	Albuterol	45 ng/mL
	QVAR® Beconase AQ <sup>2</sup>	Beclomethasone	15 ng/mL
Nasal corticosteroids	Dexacort <sup>2</sup>	Dexamethasone	12 µg/mL
	Nasacort	Triamcinolone	5% v/v
	Flonase	Fluticasone	5% v/v
	Rhinocort	Budesonide	5% v/v
	Nasonex <sup>2</sup>	Mometasone	0.5 ng/mL
	AEROSPAN® <sup>2</sup>	Flunisolide	10 µg/mL
Nasal gel	Zicam® (Allergy Relief)	Luffa operculata, Galphimia, Glauca, Histaminum hydrochloricum, Sulfur	5% v/v
Throat lozenge	Cepacol Extra Strength	Benzocaine, Menthol	0.7 mg/mL
Anti-viral drug	Relenza® <sup>2</sup>	Zanamivir	3.3 mg/mL
	TamiFlu <sup>2</sup>	Oseltamivir	400 µg/mL
	Virazole <sup>2</sup>	Ribavirin	10.5 µg/mL
Antibiotic, nasal ointment	Bactroban cream <sup>2</sup>	Mupirocin	1.6 µg/mL
Antibiotic, systemic	Tobramycin	Tobramycin	33.1 µg/mL

<sup>1</sup> v/v: volume by volume

<sup>2</sup> Active ingredients tested



## Assay Precision

Panther Fusion SARS-CoV-2/Flu A/B/RSV assay within-lab precision was evaluated with a 5-member panel consisting of virus in negative clinical NP swab VTM/UTM matrix. The 5-member panel included one negative and four dual positive panel members. The panels were tested by two operators on two runs per day, using three reagent lots on three Panther Fusion systems over twelve days.

The panel members are described in Table 7, along with a summary of the agreement with the expected results and the Ct mean and variability analysis between reagent lots, operators, instruments, between and within runs, and overall (total).

Table 7: Signal Variability of the Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay by Panel Member

Panel	Description	Analyte	Agreed/N*	Agreement (%)	Mean Ct	Between Lots		Between Instrument		Between Operators		Between Days		Between Runs		Within Run		Total	
						SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
1	Neg	Internal Control	95/96	99	33.7	0.19	0.57	0.08	0.23	0.00	0.00	0.00	0.00	0.21	0.62	0.29	0.86	0.42	1.23
2	SARS-CoV-2/Flu A Low Pos	Flu A	96/96	100	35.1	0.33	0.93	0.06	0.17	0.00	0.00	0.00	0.00	0.30	0.85	0.56	1.59	0.72	2.04
		SARS-CoV-2	96/96	100	35.9	0.00	0.00	0.13	0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.60	1.67	0.61	1.71
3	Flu B/RSV Low Pos	Flu B	96/96	100	36.0	0.14	0.40	0.09	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.36	0.99	0.39	1.09
		RSV	96/96	100	36.1	0.12	0.33	0.28	0.77	0.00	0.00	0.00	0.00	0.37	1.04	0.53	1.46	0.71	1.97
4	SARS-CoV-2/Flu A Mod Pos	Flu A	96/96	100	33.9	0.23	0.66	0.00	0.00	0.00	0.00	0.19	0.56	0.00	0.00	0.47	1.37	0.55	1.63
		SARS-CoV-2	96/96	100	34.7	0.21	0.62	0.16	0.45	0.06	0.17	0.00	0.00	0.00	0.00	0.45	1.30	0.52	1.51
5	Flu B/RSV Mod Pos	Flu B	96/96	100	34.7	0.15	0.44	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.18	0.28	0.80	0.32	0.93
		RSV	96/96	100	34.5	0.10	0.30	0.18	0.51	0.00	0.00	0.00	0.00	0.00	0.00	0.40	1.15	0.44	1.29

\*Agreement to expected panel positivity result.

Low Pos = Both targets are at 2X LoD.

Mod Pos = Both targets are at 5X LoD.

Note: Variability from some factors may be numerically negative, which can occur if the variability due to those factors is very small. When this occurs, SD=0 and CV=0%.

## Carryover Contamination

The carryover contamination rate of the assay was demonstrated using the Enhanced Direct Load Tube (RespDirect Collection Kit) using a checkerboard design, with panels made of pooled clinical matrix. A total of 300 negatives interspersed with 301 positive samples (spiked with Flu A to  $1 \times 10^4$  TCID<sub>50</sub>/mL or 90,909X LoD) were tested across 5 runs on two Panther Fusion instruments. The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay had a 0% carryover rate.

## Collection Device Equivalency

Equivalence between NP specimens collected into VTM/UTM and eSTM was evaluated by testing individual negative specimens and contrived positive panels prepared from paired negative clinical NP swab specimens collected from patients with symptoms of respiratory infection. Contrived panels were prepared by spiking individual donor paired NP specimens with SARS-CoV-2, Flu A, Flu B, and RSV to 2X and 5X LoD.

The results of the negative and contrived panels demonstrated similar agreement between the two collection devices (Table 8).

*Table 8: Results of negative and contrived panels composed of paired individual donor NP clinical specimens, collected with each collection device spiked with SARS-CoV-2, Flu A, Flu B, and RSV*

Analyte	Sample Concentration	N per Collection Device	VTM/UTM % Positive	RespDirect % Positive
None (negative sample)	0	181	0	0
SARS-CoV-2	2X LoD	50	100	98
	5X LoD	50	100	100
Flu A	2X LoD	25	100	100
	5X LoD	25	100	100
Flu B	2X LoD	25	100	100
	5X LoD	25	100	100
RSV	2X LoD	25	100	100
	5X LoD	25	100	100

## Clinical Performance

### Clinical Study — NP Swab Specimens in VTM/UTM

This study was performed to demonstrate clinical performance characteristics for the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay for NP swab specimens in VTM or UTM. A prospective multicenter study was conducted using remnant NP swab specimens from male and female individuals of all ages exhibiting signs and/or symptoms of respiratory infection consistent with COVID-19, influenza, or RSV. Five participating US pediatric/adolescent, private and/or university hospitals prospectively provided remnant NP swab specimens collected during portions of the 2020-2021 and 2021-2022 respiratory infection seasons. Due to low prevalence of positive Flu A, Flu B, and RSV specimens, the prospective specimen population was supplemented with retrospective specimens. Retrospective NP specimens with known positive results from a validated test for Flu A, Flu B, and/or RSV were obtained from two US clinical specimen suppliers. All specimens were tested with the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and with an FDA-cleared NAAT for Flu A/B/RSV, and up to three EUA or validated molecular assays for SARS-CoV-2. EUA or FDA-cleared NAATs were used for discordant resolution testing. Positive (PPA) and negative (NPA) percent agreement, with corresponding 2-Sided 95% Score CIs, were estimated relative to comparator results, by target virus, and by specimen category.

Of the 2051 total specimens included in the study, 45 were withdrawn (due to mishandling at the site or during transport). There were 2000 specimens processed in valid Panther Fusion SARS-CoV-2/Flu A/B/RSV assay runs, 1996 (99.8%) had final valid results, and 4 (0.2%) had final invalid results. Of the 1996 specimens with valid Panther Fusion results, 1995 samples were evaluable for analyses for at least 1 target virus; not all specimens were evaluable for each virus (see Table 9).

Table 9: Summary of Subject Demographics for All NP Swab Specimens

		N (%)
<b>Total</b>		1995 (100)
<b>Sex</b>	Female	1100 (55.1)
	Male	894 (44.8)
	Unknown	1 (0.1)
<b>Age Group</b>	<5 years	404 (20.3)
	5-21 years	447 (22.4)
	22 to 40 years	387 (19.4)
	41 to 60 years	342 (17.1)
	> 60 years	415 (20.8)

Of the 1900 evaluable prospective specimens tested using the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay, 21.3% (401/1887) were positive for SARS-CoV-2, 6.9% (126/1837) were positive for Flu A, 0.2% (4/1837) were positive for Flu B, and 0.6% (11/1837) were positive for RSV. Five co-infections detected by comparator testing were also detected by the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay: 3 SARS-CoV-2 positive/Flu A positive, 1 Flu A positive/Flu B positive, 1 Flu A positive/RSV positive.

Performance characteristics for detection of SARS-CoV-2, Flu A, Flu B, and RSV are shown in Table 10 through Table 13.

Table 10: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for SARS-CoV-2 with NP Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
SARS-CoV-2	Prospective	1887	378	23 <sup>3</sup>	1474	12 <sup>4</sup>	20.7	96.9 (94.7, 98.2)	98.5 (97.7, 99.0)

CI = confidence interval, FN = false negative, FP = false positive, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>Only 11 specimens with discordant results underwent additional testing due to volume restrictions. 7/11 false positive results were negative for SARS=CoV-2 by an alternate NAAT.

<sup>4</sup>Only 5 specimens with discordant results underwent additional testing due to volume restrictions. 5/5 false negative results were positive for SARS-CoV-2 by an alternate NAAT.

Table 11: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for Flu A with NP Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
Flu A	Prospective	1837	121	5 <sup>3</sup>	1709	2 <sup>4</sup>	6.7	98.4 (94.3, 99.6)	99.7 (99.3, 99.9)
	Retrospective	28	27	N/A	N/A	1 <sup>5</sup>	N/A	96.4 (82.3, 99.4)	N/A

CI = confidence interval, FN = false negative, FP = false positive, N/A = not applicable, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>Only 2 specimens with discordant results underwent additional testing due to volume restrictions. 2/2 false positive results were negative for Flu A by an alternate NAAT.

<sup>4</sup>Insufficient volume of neat specimen available for additional testing.

<sup>5</sup>1/1 false negative result was positive for Flu A by an alternate NAAT.

Table 12: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for Flu B with NP Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
Flu B	Prospective	1837	0	4 <sup>3</sup>	1833	0	0.0	NC	99.8 (99.4, 99.9)
	Retrospective	21	20	N/A	N/A	1 <sup>4</sup>	N/A	95.2 (77.3, 99.2)	N/A

CI = confidence interval, FN = false negative, FP = false positive, N/A = not applicable, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>Only 1 specimen with a discordant result underwent additional testing due to volume restrictions. 1/1 false positive result was negative for Flu B by an alternate NAAT.

<sup>4</sup>1/1 false negative result was positive for Flu B by an alternate NAAT.

Table 13: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for RSV with NP Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
RSV	Prospective	1837	11	0	1824	2 <sup>3</sup>	0.7	84.6 (57.8, 95.7)	100 (99.8, 100)
	Retrospective	46	46	N/A	N/A	0	N/A	100 (92.3, 100)	N/A

CI = confidence interval, FN = false negative, FP = false positive, N/A = not applicable, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>The 2 specimens with false negative RSV results had Ct values of 41.3 and 43.5 with the reference assay; these discordant specimens did not undergo additional testing

## Clinical Study — Nasal Swab Specimens

This study was performed to demonstrate clinical performance characteristics for the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay in nasal swab specimens. A prospective multi-center study was conducted using nasal swab specimens from male and female individuals of all ages exhibiting signs and/or symptoms of respiratory infection consistent with COVID-19, influenza, or RSV. Due to low prevalence of positive Flu A, Flu B, and RSV specimens in the all comers enrollment, the prospective specimen population was supplemented with specimens from two additional collections: (1) retrospective nasal specimens in UTM/VTM with known positive results for at least one of these viruses, and (2) prospectively collected specimens in eSTM from an enriched patient population selected based on a recent positive standard of care PCR-based result for at least one of these viruses. Thirteen participating US pediatric/adolescent, private and/or university hospitals prospectively enrolled individuals during the 2022-2023 and 2023-2024 respiratory seasons and collected nasal swab specimens using a standard flocked swab and stored in VTM/UTM and using the RespDirect flocked swab and stored in RespDirect eSTM.

All specimens were tested with the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and with an FDA-cleared NAAT for Flu A/B/RSV, and up to three EUA or validated molecular assays for SARS-CoV-2. Positive (PPA) and negative (NPA) percent agreement, with corresponding 2-Sided 95% Score CIs, were estimated relative to comparator results by target virus for specimens in VTM/UTM and RespDirect eSTM separately.

Of the 2511 prospectively enrolled individuals, 12 did not meet eligibility criteria and were withdrawn. None of the 175 retrospective specimens in VTM/UTM were withdrawn. There were 2640 specimens processed in valid Panther Fusion SARS-CoV-2/Flu A/B/RSV assay runs; 1399 (99.7%) specimens in VTM/UTM and 1230 (99.4%) specimens in RespDirect eSTM had final valid results. The 2414 prospectively enrolled individuals evaluable for the performance analyses for at least 1 target virus included 1189 with evaluable nasal swab specimens in VTM/UTM, and 1225 with evaluable nasal swab specimens in RespDirect eSTM. One hundred seventy three (173) retrospective specimens were evaluable for the performance analyses for Flu A, Flu B, and RSV. Not all specimens were evaluable for each virus. Table 14 summarizes the demographics for all enrolled individuals with evaluable nasal swab specimens.

Table 14: Summary of Individuals' Demographics for All Nasal Swab Specimens

		Prospective VTM/UTM	Retrospective VTM/UTM	Prospective RespDirect eSTM	Enrichment RespDirect eSTM
		N (%)	N (%)	N (%)	N (%)
Total		1189 (100)	173	1021	204
Sex	Female	715 (60.1)	94 (54.3)	594 (58.2)	119 (58.3)
	Male	474 (39.9)	79 (45.7)	427 (41.8)	85 (41.7)
Age Group	Mean	39.9	16.0	41.5	30.0
	Median	39.0	7.0	40.0	24.0
	Minimum	0	0	0	0
	Maximum	87	83	90	87

Two co-infections detected by comparator testing were also detected by the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay in specimens in UTM/VTM: 1 SARS-CoV-2 positive/RSV positive, 1 Flu A positive/RSV positive. Eight co-infections were detected by the Panther Fusion

SARS-CoV-2/Flu A/B/RSV assay in specimens in RespDirect eSTM: 1 SARS-CoV-2 positive/Flu B positive, 1 SARS-CoV-2 positive/Flu A positive, 1 SARS-CoV-2 positive/RSV positive, 4 Flu A positive/RSV positive, and 1 Flu B positive/RSV positive.

Performance characteristics for detection of SARS-CoV-2, Flu A, Flu B, and RSV are shown in Table 15 through Table 18.

Table 15: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for SARS-CoV-2 for Nasal Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
SARS-CoV-2	Prospective (VTM/UTM)	1187	144	12	1023	8	12.8	94.7 (90.0, 97.3)	98.8 (98.0, 99.3)
	Prospective (eSTM)	1019	109	9	900	1	10.8	99.1 (95.0, 99.8)	99.0 (98.1, 99.5)

CI = confidence interval, FN = false negative, FP = false positive, NPA = negative percent agreement, PPA = positive percent agreement, TP = true positive, TN = true negative.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

Table 16: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for Flu A for Nasal Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
Flu A	Prospective (VTM/UTM)	1189	45	5	1135	4	4.1	91.8 (80.8, 96.8)	99.6 (99.0, 99.8)
	Retrospective (VTM/UTM)	173	47	2	123	1	N/A	97.9 (89.1, 99.6)	98.4 (94.4, 99.6)
	Prospective (eSTM)	1021	11	1	1009	0	1.1	100 (74.1-100)	99.0 (99.4, 100)
	Enrichment (eSTM)	71	69	N/A	N/A	2	N/A	97.2 (90.3, 99.2)	N/A <sup>3</sup>

CI = confidence interval, FN = false negative, FP = false positive, N/A = not applicable, NPA = negative percent agreement, PPA = positive percent agreement, TP = true positive, TN = true negative.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>All specimens enrolled in the enrichment study were standard of care positive for Flu A, Flu B, and/or RSV. NPA was not applicable for enrichment study specimens.

Table 17: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for Flu B for Nasal Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
Flu B	Prospective (VTM/UTM)	1189	2	3	1183	1	0.3	66.7 (20.8, 93.9)	99.7 (99.3, 99.9)
	Retrospective (VTM/UTM)	173	69	0	102	2	N/A	97.2 (90.3, 99.2)	100 (96.4, 100)
	Prospective (eSTM)	1021	5	2	1013	1	0.6	83.3 (43.6, 97.0)	99.8 (99.3, 99.9)
	Enrichment (eSTM)	45	44	N/A	N/A	1	N/A	97.8 (88.4, 99.6)	N/A <sup>3</sup>

CI = confidence interval, FN = false negative, FP = false positive, N/A = not applicable, NPA = negative percent agreement, PPA = positive percent agreement, TP = true positive, TN = true negative.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>All specimens enrolled in the enrichment study were standard of care positive for Flu A, Flu B, and/or RSV. NPA was not applicable for enrichment study specimens

Table 18: Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Performance for RSV for Nasal Swab Specimens

Analyte	Specimen Category	N	TP	FP	TN	FN	Prevalence <sup>1</sup> (%)	PPA (95% CI) <sup>2</sup>	NPA (95% CI) <sup>2</sup>
RSV	Prospective (VTM/UTM)	1189	17	2	1169	1	1.5	94.4 (74.2, 99.0)	99.8 (99.4, 100)
	Retrospective (VTM/UTM)	173	49	1	122	1	N/A	98.0 (89.5, 99.6)	99.2 (95.5, 99.9)
	Prospective (eSTM)	1021	1	1	1019	0	0.1	100 (20.7, 100)	99.9 (99.4, 100)
	Enrichment (eSTM)	61	60	N/A	N/A	1	N/A	98.4 (91.3, 99.7)	N/A <sup>3</sup>

CI = confidence interval, FN = false negative, FP = false positive, N/A = not applicable, NPA = negative percent agreement, PPA = positive percent agreement, TP = true positive, TN = true negative.

<sup>1</sup>Study prevalence reported.

<sup>2</sup>Score CI.

<sup>3</sup>All specimens enrolled in the enrichment study were standard of care positive for Flu A, Flu B, and/or RSV. NPA was not applicable for enrichment study specimens.



## Reproducibility

Panther Fusion SARS-CoV-2/ Flu A/B/RSV assay reproducibility was evaluated at three US sites using one negative and four dual positive panel members. Testing was performed using one lot of assay reagents and six operators (two at each site). At each site, testing was performed for at least five days. Each run had three replicates of each panel member.

A negative panel member was created using pooled negative clinical NP swab specimens in VTM/UTM processed into STM (i.e., negative matrix). Positive panel members were created by spiking 1-2X LoD (low-positive) or 3X-5X LoD (moderate-positive) concentrations of the target analyte into the negative matrix.

The agreement with expected results was 100% for all panel members components for SARS-CoV-2, Flu A, Flu B, and RSV (Table 19) except the following: 98.9% in both the negative panel member and in the low positive Flu A panel member component.

*Table 19: Agreement of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Results with Expected Results*

Panel	Description	Analyte	Agreement with Expected Results	
			N	95% CI (%)
1	Neg	Internal Control	89/90	98.9 (94.0-99.8)
2	SARS-CoV-2/Flu A Low Pos	Flu A	89/90	98.9 (94.0-99.8)
		SARS-CoV-2	90/90	100 (95.9-100)
3	Flu B/RSV Low Pos	Flu B	90/90	100 (95.9-100)
		RSV	90/90	100 (95.9-100)
4	SARS-CoV-2/Flu A Mod Pos	Flu A	90/90	100 (95.9-100)
		SARS-CoV-2	90/90	100 (95.9-100)
5	Flu B/RSV Mod Pos	Flu B	90/90	100 (95.9-100)
		RSV	90/90	100 (95.9-100)

CI = Score confidence interval; Mod =moderate; Neg =negative; Pos =positive

Low Pos = Both targets are at 1-2X LoD.

Mod Pos = Both targets are at 3-5X LoD.

The total SARS-CoV-2, Flu A, Flu B, and RSV signal variability measured as %CV was  $\leq 1.82\%$  (SD 0.30 to 0.65) for all moderate panel components and for low moderate panel components for SARS-CoV-2, Flu B, and RSV (Table 20). The %CV and SD for the Flu A low positive panel component were 10.92% and 3.77, respectively, due to the false negative result for one replicate. For the sources of variation except the 'within run' factor, %CV values were  $\leq 0.62\%$  for all panel member components.

Table 20: Signal Variability of the Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay by Panel Member

Panel	Description	Analyte	N	Mean Ct	Between Sites		Between Operators/Runs <sup>1</sup>		Between Days		Within Runs		Total	
					SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
2	SARS-CoV-2/Flu A Low Pos	Flu A	90	34.55	0.57	1.66	0.62	1.81	0.00	0.00	3.68	10.64	3.77	10.92
		SARS-CoV-2	90	35.53	0.24	0.68	0.18	0.50	0.19	0.52	0.49	1.38	0.60	1.70
3	Flu B/RSV Low Pos	Flu B	90	35.80	0.12	0.35	0.00	0.00	0.22	0.60	0.39	1.10	0.47	1.30
		RSV	90	35.78	0.07	0.20	0.23	0.65	0.14	0.39	0.59	1.64	0.65	1.82
4	SARS-CoV-2/Flu A Mod Pos	Flu A	90	33.55	0.09	0.27	0.03	0.10	0.17	0.49	0.48	1.42	0.51	1.53
		SARS-CoV-2	90	34.15	0.11	0.32	0.00	0.00	0.00	0.00	0.40	1.16	0.41	1.20
5	Flu B/RSV Mod Pos	Flu B	90	34.56	0.00	0.00	0.10	0.29	0.00	0.00	0.29	0.83	0.30	0.88
		RSV	90	34.41	0.05	0.14	0.00	0.00	0.00	0.00	0.43	1.25	0.43	1.26

Ct = threshold cycle, CV = coefficient of variation, Mod = moderate, Pos = positive, SD = standard deviation

Note: Variability from some factors may be numerically negative; in these cases, SD and %CV are displayed as 0.

Low Pos = Both targets are at 1-2X LoD.

Mod Pos = Both targets are at 3-5X LoD.

<sup>1</sup> Between Operator may be confounded with Between Run; therefore, Between Operator and Between Run estimates are combined in Between Operator/Run.

The signal variability measured as %CV was  $\leq 1.50\%$  ( $SD \leq 0.48$ ) between sites, between operators, between days, or overall for the Panther Fusion SARS-CoV-2, Flu A, Flu B, and RSV assay positive controls (Table 21)..

Table 21: Signal Variability of the Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Controls

Control	Analyte	N	Mean Ct	Between Sites		Between Operators		Between Days		Within Runs		Total	
				SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
Pos	SARS-CoV-2	30	33.44	0.06	0.18	0.14	0.41	0.19	0.57	0.29	0.87	0.38	1.13
	Flu A	30	31.75	0.27	0.86	0.00	0.00	0.00	0.00	0.39	1.22	0.48	1.50
	Flu B	30	31.28	0.14	0.43	.005	0.15	0.02	0.07	0.24	0.76	0.28	0.89
	RSV	30	32.55	0.06	0.20	0.00	0.00	0.00	0.00	0.28	0.87	0.29	0.89

Ct = threshold cycle; CV = coefficient of variation; Pos = positive; SD = standard deviation

Note: Variability from some factors may be numerically negative; in these cases, SD and %CV are displayed as 0.

## Bibliography

1. Centers for Disease Control and Prevention. <https://www.cdc.gov/covid/signs-symptoms>. Accessed June 25, 2024.
2. Centers for Disease Control and Prevention. [https://www.cdc.gov/rsv/about/?CDC\\_AAref](https://www.cdc.gov/rsv/about/?CDC_AAref). Accessed August 30, 2024.
3. Centers for Disease Control and Prevention. [https://www.cdc.gov/flu/signs-symptoms/?CDC\\_AAref](https://www.cdc.gov/flu/signs-symptoms/?CDC_AAref). Accessed August 26, 2024
4. Centers for Disease Control and Prevention. [https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html?CDC\\_AAref](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html?CDC_AAref). Accessed December, 9, 2024
5. Akers IE, Weber R, Sax H, Böni J, Trkola A, Kuster SP. Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study. *Influenza Other Respir Viruses*. 2017;11(4):337-344. doi:10.1111/irv.12454.
6. Couch, R.B. and Kasel, J.A. 1995. Influenza in *Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections*. 7<sup>th</sup> Edition. 431-446.
7. Harper, S.A., Fukida, K., Uyeki, T.M., Cox, N.J., and Bridges, C.B. 2005. Prevention and Control of Influenza. *MMWR*. 54(RR08):1-40.
8. World Health Organization. Influenza (Seasonal). <http://www.who.int/mediacentre/factsheets/fs211/en/>.
9. Centers for Disease Control and Prevention. Respiratory Syncytial Virus (RSV) Research & Surveillance. <https://www.cdc.gov/rsv/research/index.html>. Accessed March 18, 2024.
10. Centers for Disease Control and Prevention. <https://www.cdc.gov/covid/about/index.html>. Accessed June 25, 2024
11. Centers for Disease Control and Prevention. [https://www.cdc.gov/covid/signs-symptoms/?CDC\\_AAref](https://www.cdc.gov/covid/signs-symptoms/?CDC_AAref). Accessed June 25, 2024.
12. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. 2020 Mar 19;91(1):157-160. doi: 10.23750/abm.v91i1.9397. PMID: 32191675; PMCID: PMC7569573.
13. World Health Organization. Coronavirus disease (COVID-19). [https://www.who.int/health-topics/coronavirus#tab=tab\\_1](https://www.who.int/health-topics/coronavirus#tab=tab_1). Accessed March 18, 2024

## Contact Information



Hologic, Inc.  
10210 Genetic Center Drive  
San Diego, CA 92121 USA



**Australian Sponsor**  
Hologic (Australia & New  
Zealand) Pty Ltd.  
Macquarie Park NSW 2113

For country-specific Technical Support and Customer Service email address and telephone number, visit [www.hologic.com/support](http://www.hologic.com/support).

Hologic, Aptima, Panther, Panther Fusion, and RespDirect are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

All other trademarks that may appear in this package insert are the property of their respective owners.

This product may be covered by one or more U.S. patents identified at [www.hologic.com/patents](http://www.hologic.com/patents).

©2025 Hologic, Inc. All rights reserved.

AW-33210-001 Rev. 001  
2025-02